<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081819</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2015_SH003</org_study_id>
    <nct_id>NCT03081819</nct_id>
  </id_info>
  <brief_title>A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer</brief_title>
  <official_title>A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I study of SH003 for evaluate safe dose range in patients with solid cancer.&#xD;
&#xD;
      The first dose group receives SH003 for 3 weeks. If the adverse events occur in less than one&#xD;
      in six participants, the dose is escalated.&#xD;
&#xD;
      The second dose group receives SH003 for 3 weeks. If the adverse events occur in less than&#xD;
      one in six participants, the dose is escalated.&#xD;
&#xD;
      The third dose group receives SH003 for 3 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Actual">July 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 weeks</time_frame>
    <description>Grade 3-4 adverse event using CTCAE v4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>SH003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will take SH003 for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH003</intervention_name>
    <description>Herbal medicine for cancer treatment</description>
    <arm_group_label>SH003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19 years or older&#xD;
&#xD;
          -  Patients with histologically and cytologically confirmed solid tumor&#xD;
&#xD;
          -  Patients who have failed standard treatments, such as previous chemotherapy or&#xD;
             radiotherapy, or who are inoperable, refractory, or progressive.&#xD;
&#xD;
          -  ECOG score 0-2&#xD;
&#xD;
          -  Patients with a minimum life expectancy of 12 weeks at the scheduled starting date of&#xD;
             the study drug&#xD;
&#xD;
          -  Previous treatment with surgery or radiotherapy, at least 4 weeks since end of&#xD;
             treatment is allowed (the patient should have been recovered from any side effects.&#xD;
&#xD;
          -  Patients who can swallow pills.&#xD;
&#xD;
          -  Patients who provide written informed consent for participation in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any study drug component, including Astragalus membranaceus,&#xD;
             Angelica gigas, or Trichosanthes Kirilowii Maximowicz&#xD;
&#xD;
          -  Patients with pre-existing cardiac conditions:&#xD;
&#xD;
          -  Prior documented myocardial infarction within the last 6 months&#xD;
&#xD;
          -  Pre-existing cardiac failure (NYHA class III-IV)&#xD;
&#xD;
          -  Atrial fibrillation on anti-coagulants&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Severe valvulopathy&#xD;
&#xD;
          -  Cardiac angioplasty or stenting with in the last 6 months&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other&#xD;
             condition (including laboratory abnormalities) that could interfere with patient&#xD;
             safety&#xD;
&#xD;
          -  Active uncontrolled infection, including known history of AIDS or hepatitis B or C&#xD;
&#xD;
          -  Any psychological, sociological, or geographical condition that could potentially&#xD;
             interfere with compliance with the study protocol&#xD;
&#xD;
          -  Concurrently receiving any other investigational agents while on study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Seong-Gyu Ko</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

